Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics Inc.

Anika Therapeutics, Inc. (($ANIK)) has held its Q1 earnings call. Read on for the main highlights of the call. Anika Therapeutics’ latest earnings ...

Anika Therapeutics Signals Momentum Amid Regulatory Risks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD), Anika Therapeutics (ANIK) and I...

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Anika Therapeutics (ANIK) and Insulet (PODD)

Anika Therapeutics Signals Momentum Amid Regulatory Hurdles

Anika Therapeutics ( ($ANIK) ) has issued an announcement. Anika Therapeutics reported a strong start to 2026, with first-quarter revenue on April ...

Market Cap	$142.05M	P/E Ratio	N/A
52W High	$16.24	52W Low	$7.87
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	9.3%	52W Position	83.9%
Overall Score	57	Value Score	60
Quality Score	47	Technical Score	66

EPS Current Est	$-0.74	EPS Next Est	$-0.43
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANIK	$14.89	+0.54%	6.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ANIK	$14.89	+0.5%	6.88K
3
4
5
6

ANIK

ANIK

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Anika Therapeutics Inc. Data in Excel

Get Anika Therapeutics Inc. Data in Excel